Third patient implanted with Ventracor device
Thursday, 23 October, 2003
Ventracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
According to the chief medical investigator Prof Don Esmore, the patient is in a critical but stable condition.
He said the patient was gravely ill at the time of the procedure, and the implant was the only option available.
The announcement comes a couple of weeks after the second patient to receive the implant was discharged from hospital. The company plans to test up to ten patients in the pilot trial, before embarking on a larger, international trial.
Ventracor's share price rose four per cent yesterday after the announcement was made to close at AUD$2.49.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
